Curaleaf Holdings, Inc.
CURA.TOTSXHealthcare● Active
$15.70
$-0.51(-3.15%)
Market Cap$3.7B
P/E Ratio—
52W High$16.92
52W Low$0.99
Curaleaf Holdings, Inc. (CURA.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CURA.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.38
Est. -$0.10 · +487.0%
Revenue
$0.45B
Est. $0.44B · +2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
CURA.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.49B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.49B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.25 | — | — | — | $0.46B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.10 | $0.38 | +487.0% | $0.45B | $0.44B | +2.6% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.10 | -$0.08 | +19.4% | $0.46B | $0.45B | +0.9% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.10 | -$0.09 | +10.7% | $0.45B | $0.44B | +1.1% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.09 | -$0.08 | +7.9% | $0.43B | $0.43B | +0.3% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.09 | -$0.10 | -9.8% | $0.45B | $0.45B | -0.6% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.09 | -$0.14 | -59.9% | $0.48B | $0.48B | -0.3% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.08 | -$0.07 | +17.1% | $0.45B | $0.46B | -3.7% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.38
EPS Est.
-$0.10
EPS Surpr.
+487.0%
Revenue
$0.45B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.10
EPS Surpr.
+19.4%
Revenue
$0.46B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.10
EPS Surpr.
+10.7%
Revenue
$0.45B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.09
EPS Surpr.
+7.9%
Revenue
$0.43B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.09
EPS Surpr.
-9.8%
Revenue
$0.45B
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.09
EPS Surpr.
-59.9%
Revenue
$0.48B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+17.1%
Revenue
$0.45B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q4 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q3 FY2026 | $-0.06 | $-0.06 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.4B | $0.4B | $0.4B | 3 |
| Q3 FY2027 | $0.4B | $0.4B | $0.4B | 3 |
| Q2 FY2027 | $0.4B | $0.4B | $0.4B | 3 |
| Q1 FY2027 | $0.3B | $0.3B | $0.4B | 4 |
| Q4 FY2026 | $0.3B | $0.3B | $0.4B | 4 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +487.0% | $15.54 | $16.08 | +3.47% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +19.4% | $10.26 | $9.99 | -2.63% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +10.7% | $11.28 | $12.03 | +6.65% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +7.9% | $7.83 | $6.93 | -11.49% |
| ▼ Q2 FY2025 | May 8, 2025 | -9.8% | $3.57 | $3.63 | +1.68% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -59.9% | $5.79 | $5.25 | -9.33% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +17.1% | $13.02 | $9.12 | -29.95% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +0.0% | $13.92 | $13.20 | -5.17% |
Q2 FY2026+3.47%
Report Date
May 7, 2026
EPS Beat/Miss
+487.0%
Price Before
$15.54
Price After
$16.08
Q1 FY2026-2.63%
Report Date
Feb 26, 2026
EPS Beat/Miss
+19.4%
Price Before
$10.26
Price After
$9.99
Q4 FY2025+6.65%
Report Date
Nov 5, 2025
EPS Beat/Miss
+10.7%
Price Before
$11.28
Price After
$12.03
Q3 FY2025-11.49%
Report Date
Aug 6, 2025
EPS Beat/Miss
+7.9%
Price Before
$7.83
Price After
$6.93
Q2 FY2025+1.68%
Report Date
May 8, 2025
EPS Beat/Miss
-9.8%
Price Before
$3.57
Price After
$3.63
Q1 FY2025-9.33%
Report Date
Mar 3, 2025
EPS Beat/Miss
-59.9%
Price Before
$5.79
Price After
$5.25
Q4 FY2024-29.95%
Report Date
Nov 6, 2024
EPS Beat/Miss
+17.1%
Price Before
$13.02
Price After
$9.12
Q3 FY2024-5.17%
Report Date
Aug 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$13.92
Price After
$13.20
Avg Beat Reaction-6.52%
Avg Miss Reaction-3.83%
Beat Rate6 / 8 quarters
Largest Move-29.95% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CURA.TO ends December
Curaleaf Holdings, Inc. (CURA.TO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.38 — beating the analyst consensus of $-0.10 by +487.0%. CURA.TO has beaten EPS estimates for 4 consecutive quarters. The next CURA.TO earnings date is expected around September 1, 2026.
Each quarter, investors track CURA.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CURA.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CURA.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CURA.TO earnings · 5 questionsCuraleaf Holdings, Inc.'s next earnings report is expected around September 1, 2026. CURA.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CURA.TO historically reports after market close (AMC).
CURA.TO earnings datewhen is CURA.TO earningsCURA.TO next earnings datewhen does CURA.TO report earningsCURA.TO earnings calendar
▸ Source: FMP · Curaleaf Holdings, Inc. SEC filings · US GAAP · Curaleaf Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026